Acuta Capital Partners, LLC Milestone Pharmaceuticals Inc. Transaction History

Acuta Capital Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$5.86 - $9.43 $819,380 - $1.32 Million	139,826 Added 30.58%	597,026 $5.49 Million
Q2 2022 Aug 15, 2022	BUY	$5.13 - $7.37 $396,036 - $568,964	77,200 Added 20.32%	457,200 $2.81 Million
Q1 2022 May 16, 2022	BUY	$4.1 - $8.24 $1.56 Million - $3.13 Million	380,000 New	380,000 $2.44 Million
Q1 2020 May 15, 2020	SELL	$1.7 - $22.5 $864,450 - $11.4 Million	-508,500 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$15.4 - $21.9 $2.14 Million - $3.04 Million	139,000 Added 37.62%	508,500 $8.14 Million
Q3 2019 Nov 14, 2019	BUY	$15.67 - $25.96 $352,575 - $584,100	22,500 Added 6.48%	369,500 $6.89 Million
Q2 2019 Aug 14, 2019	BUY	$15.37 - $27.15 $5.33 Million - $9.42 Million	347,000 New	347,000 $9.42 Million

28.7M

200

Ticker MIST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,010,900
Market Cap $67.5M
Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II cl...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.